Showing results (31-40 of 94) with videos related to

Sort By:
Pageof 10
Plos One|June 30, 2015
High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer CohortHalfdan Sorbye, Anca Dragomir, Magnus Sundström, et al.
Cancer Medicine|May 10, 2019
Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patientsKristine Ø Aasebø, Anca Dragomir, Magnus Sundström, et al.
Journal of Neuroendocrinology|April 5, 2023
Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasmsHege Elvebakken, Geir Olav Hjortland, Herish Garresori, et al.
BMC Surgery|August 27, 2017
Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trialKnut Jørgen Labori, Kristoffer Lassen, Dag Hoem, et al.
British Journal of Cancer|October 13, 2022
Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancerSebastian Meltzer, Anne Negård, Kine M Bakke, et al.
Journal of Neuroendocrinology|March 16, 2023
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinomaHalfdan Sorbye, Enrique Grande, Marianne Pavel, et al.
Therapeutic Advances in Medical Oncology|July 29, 2025
Pancreatic neuroendocrine tumors and MUTYH pathogenic variants: a multinational studyRachel P Riechelmann, Giovana T Torrezan, Emily Bergsland, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 7, 2016
A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancerGeorg Dimcevski, Spiros Kotopoulis, Tormod Bjånes, et al.
Neuroendocrinology|August 29, 2018
Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)Halfdan Sorbye, Eric Baudin, Ivan Borbath, et al.
Annals of Surgical Oncology|December 19, 2015
Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative StudySven-Petter Haugvik, Eva Tiensuu Janson, Pia Österlund, et al.
Pageof 10